The FDA issued a supplemental approval for Casgevy (exagamglogene autotemcel) extending its indication to patients aged 2 years and older with sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta-thalassemia. Previously approved only for patients 12 and older, this is the first gene therapy cleared for pediatric sickle cell patients in this younger age group.
Healthcare & FDA
FDA Expands Casgevy to Children as Young as 2, Widening the Market for Vertex and CRISPR Therapeutics
Lowering the approved age for the first CRISPR gene therapy from 12 to 2 years old meaningfully expands the addressable patient population — and the revenue runway.
1-YEAR MOVE
VRTX
▲22.1%
| Ticker | Company | 1-year change |
|---|---|---|
| VRTX | Vertex Pharmaceuticals | +22.1% |
For CRISPR Therapeutics, Casgevy is the primary commercial asset — any label expansion is a direct revenue catalyst.
Who cashes in: Vertex Pharmaceuticals VRTX and CRISPR Therapeutics CRSP co-developed and co-commercialize Casgevy, splitting economics roughly equally. The pediatric expansion matters because sickle cell disease is often diagnosed and begins causing serious damage in early childhood — catching patients at age 2 rather than waiting until 12 means more eligible patients, earlier treatment, and potentially better clinical outcomes that support the therapy's $2.2 million list price. VRTX is the larger, more diversified company; CRSP is the higher-beta pure-play on this approval. For CRSP specifically, Casgevy is the primary commercial asset, so any label expansion is a direct revenue catalyst.
Who's exposed: bluebird bio (BLUE) markets Lyfgenia, its competing gene therapy for sickle cell disease. A broader Casgevy label — especially one covering younger patients where bluebird has no equivalent approval — puts additional competitive pressure on a company already navigating a difficult commercial launch and a fragile balance sheet.
What to watch next: Actual treatment uptake in the 2–11 age cohort. Gene therapy for young children involves significant logistical and clinical complexity; the label expansion is necessary but not sufficient for revenue. Watch VRTX and CRSP quarterly updates for pediatric site activations and patient starts.
Source: original report ↗
Free alerts
Free: catalyst alerts, straight to your inbox.
Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $40/moJoin the owners who run ahead of the industry. Cancel anytime, one click.